NEW YORK (GenomeWeb News) – GE Healthcare said today it has expanded its licensing agreement with Geron for the development of cellular assays and models derived from embryonic stem cells.

The assays and models are for use in drug discovery and toxicity screening, and under the terms of the expanded deal, GE has exclusive rights to Geron's IP and know-how for developing and selling cellular assays derived from induced pluripotent stem cells.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A draft bill released by the US House of Representatives appropriations committee would increase the 2019 National Institutes of Health budget by 3 percent.

Bloomberg looks into privacy issues raised by law enforcement's use of genetic genealogy sites.

NBC News reports on the Earth BioGenome Project, which aims to sequence all eukaryotic life on Earth.

In Science this week: environmental DNA can help in studies of marine animals, and more.